Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
about
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsFunctional brain imaging: an evidence-based analysisChronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.Convergence of presenilin- and tau-mediated pathways on axonal trafficking and neuronal function.S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro.Chitosan Oligosaccharides Inhibit/Disaggregate Fibrils and Attenuate Amyloid β-Mediated Neurotoxicity.Compliance and Caregiver Satisfaction in Alzheimer's Disease: Results from the AXEPT Study.Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?Yam (Dioscorea pseudojaponica Yamamoto) ameliorates cognition deficit and attenuates oxidative damage in senescent mice induced by D-galactose.Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine.Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.Anti-acetylcholinesterase activity and antioxidant properties of extracts and fractions of Carpolobia lutea.The Black Book of Psychotropic Dosing and Monitoring.Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
P2860
Q26997299-97B278FA-0E7C-42A0-BE03-6DC9E7BAC83DQ30573784-B9AAFD01-8391-4FF4-A399-34D6FF891E2CQ33291589-AAB4BDC7-48A3-44A4-ABD5-736661A198CFQ33736233-18FA8AC5-B627-4929-A96B-9152DA13BB1DQ34232597-D60E1E9A-7DF5-4C3C-9E6F-EFA3903F926CQ34561747-A4A6EA38-6629-45E5-9690-3B251FD6EA31Q35640608-EF38587D-AC07-490D-8896-7E2E1E6FF91AQ36383025-566CA599-D9BE-436F-B7CB-6943C11DECAAQ36978147-FA0E1A55-EFD0-4099-B480-7AE668CD873FQ43249661-46AC5347-DF4E-4294-88CF-443E06020AF0Q46158129-A4B918A1-16B8-41E3-A1DE-EAC3D0945F48Q46760576-D97E78F5-4E91-48B9-B1E1-A3F712E7EA2CQ46906700-B1864D89-2EE2-4052-825F-17F50A72ED1BQ47642128-15FB5182-345A-43D3-BC45-044A68D574AEQ51557068-E795E1E8-CFED-4995-AFE5-18A13A95F70D
P2860
Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cholinesterase inhibitors in t ...... arly and persistent treatment.
@ast
Cholinesterase inhibitors in t ...... arly and persistent treatment.
@en
type
label
Cholinesterase inhibitors in t ...... arly and persistent treatment.
@ast
Cholinesterase inhibitors in t ...... arly and persistent treatment.
@en
prefLabel
Cholinesterase inhibitors in t ...... arly and persistent treatment.
@ast
Cholinesterase inhibitors in t ...... arly and persistent treatment.
@en
P2860
P1476
Cholinesterase inhibitors in t ...... arly and persistent treatment.
@en
P2093
P2860
P304
P356
10.1177/147323000603400401
P577
2006-07-01T00:00:00Z